Real-World Outcomes for First-Line Luspatercept in Lower-Risk MDS

Amer Zeidan, MBBS, reviews real-world data presented at the 2025 ASH Annual Meeting and Exposition evaluating first-line luspatercept (Reblozyl) in patients with lower-risk myelodysplastic syndromes (MDS). He discusses effectiveness outcomes, transfusion independence rates, and how these findings compare with results from clinical trials. Zeidan places these data in context of routine clinical practice and evolving treatment algorithms.